MYCN and medulloblastoma: Group 3 medulloblastomas (Myc/MycN status known in 7/16 patients, 2/7 with Myc amplification) was associated with a median PFS1stRD of 4.9 months (CI: 3.2–6.0) and median OS1stRD of 9.8 months (CI: 8.2–11.3).